Document Actions
BRR Archive
September 2009, Vol. 24 No. 8
Folotyn Receives FDA Accelerated Approval For Peripheral T-Cell Lymphoma. Poniard To Begin Data Analysis In Study Of Picoplatin For Small Cell Lung Cancer. FDA Signs Off On Phase III Design For OncoVEX In Head & Neck Cancer. Abbott, Pfizer Agree To Develop Test For NSCLC. Firm To Develop Online Educational Tools For NCCN Guidelines.
To download, subscribe to the newsletter or sign up for a one day pass.
July 2009, Vol. 24 No. 7
Alimta Approved In Europe For Advanced Or Metastatic Non-Small Cell Lung Cancer. Boehringer Ingelheim Begins Phase III Trial Of Oral EGFR Inhibitor For NSCLC. AstraZeneca Submits Applications To FDA, EMA, For Vandetanib For NSCLC.
To download, subscribe to the newsletter or sign up for a one day pass.
June 2009, Vol. 24 No. 6
Debiopharm, Moffitt Cancer Center Sign License Agreement For Small Molecule. US Oncology Launches iKnowMed Electronic Health Record System. CHMP Supports Javlor Approval For Urothelial Cancer. Merck, Oncothyreon Begin Phase III Trial Of Stimuvax. ASCO Commissions Study Of Non-Physician Health Workers.
To download, subscribe to the newsletter or sign up for a one day pass.
May 2009, Vol. 24 No. 5
ODAC Recommends Accelerated Approval Of Arzerra For Refractory Leukemia. AlphaVax Completes Enrollment Of Phase I/II Trial Of CEA Cancer Immunotherapy. FDA Forms Task Force To Recommend Ways To Improve Agency's Transparency. Amgen, FDA Agree On One Element Of Pharmacovigilance Program For Aranesp.
To download, subscribe to the newsletter or sign up for a one day pass.
April 2009, Vol.24 No. 4
Genentech Says Phase III Trial of Avastin in Colon Cancer Didn't Meet Endpoint. OncoGenex In Agreement With FDA on Prostate Cancer Trial Design. Genomic Health Says Validation Study Met Endpoint for Stage II Colon Cancer.
To download, subscribe to the newsletter or sign up for a one day pass.
March 2009 Vol. 24 No. 3
FDA Approves Novartis Agent Afinitor For Advanced Renal Cell Carcinoma. Roche Completes Purchase Of Genentech For $46.8 Billion; R&D Stays In California. Infinity Begins Phase II Trial of Heat Shock Protein Inhibitor. Pharma & Biotech Invested $65 Billion In R&D From 2007. US Oncology Forms A CRO.
To download, subscribe to the newsletter or sign up for a one day pass.
February 2009 Vol. 24 No. 2
US Oncology Earnings Down $370 Million, Company Cites ESA Safety Concerns. Amgen, Takeda Resume Enrollment In Phase III MONET1 Trial For NSCLC. Amgen Seeks FDA Approval For Denosumab In Bone Loss, And Osteoporosis Prevention. Cell Therapeutics Sells Interest In Zevalin Joint Venture.
To download, subscribe to the newsletter or sign up for a one day pass.
January 2009, Vol. 24 No. 1
Roche Offer Lower Amount For Genentech Directly To Shareholders. Algeta Says Phase II Trials Demonstrate Alpharadin Can Prolong Bone Met Survival. YM BioSciences Gets Canadian Approval For Phase II Trials. FDA Tells Alfacell Another Trial Needed For Onconase; Firm Seeks Financing.
To download, subscribe to the newsletter or sign up for a one day pass.
December 2008, Vol. 23 No. 11
FDA Approves Mozobil With G-CSF For Autologous Stem Cell Transplantation. Co-Payments To Rise As Access To Drugs Tightens For Patients On Medicare Part D. ImClone, BMS Apply To Broaden Erbitux To First-Line Treatment Of Advanced NSCLC. Merck Gives $1 Million To NCCN To Conduct Trials Of Zolinza.
To download, subscribe to the newsletter or sign up for a one day pass.
November 2008, Vol. 23 No. 10
Eli Lilly Completes Purchase of ImClone, CEO Johnson To Retain Position. Cell Therapeutics' Pixantrone Achieves Primary Endpoint in Phase III Trial in Non-Hodgkin's Lymphoma.
To download, subscribe to the newsletter or sign up for a one day pass.
October 2008, Vol. 23 No. 9
Firm Withdraws Ovarian Cancer Test After Receiving FDA Warning Letter. US Oncology Becomes Member Of RTOG. Eli Lilly, ImClone Approve Merger.
To download, subscribe to the newsletter or sign up for a one day pass.
September 2008, Vol. 23 No. 8
US Oncology Begins Service Division To Provide Evidence-Based Cancer Care. Dendreon Begins Phase II Provenge Trial; Patients Randomized To Different Doses.
To download, subscribe to the newsletter or sign up for a one day pass.
Forgot your password?